PATENT CLAIM ANALYSIS

Application Number: 15922405
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["514", "171000"]

Abstract:
Disclosed herein are pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1,4-dione. Also disclosed are methods of treating diseases and/or conditions associated with a cancer, such as prostate cancer with such pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1,4-dione. The disclosed pharmaceutical compositions may provide improved dosage for oral administration to patients in the clinic. The disclosed pharmaceutical compositions may provide improved stability and/or shelf life.

Claim (Index 6):
The method of  claim 1 , further comprising administering to the subject androgen deprivation therapy that reduces the amount of androgen in the subject, wherein the androgen deprivation therapy is selected from the group consisting of abiraterone, finasteride, dutasteride, degarelix, and leuprolide.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 90.0
- Lexical Diversity: 1.58974
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12374828', '14434060', '10107537', '13908507', '13752330']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7787128682811164
- 35 USC 102 Novelty (BERT): 0.515716508447182
- Combined Prediction Score: 0.752413232297723
- Mean Citation Score: 280.949156
- Max Citation Score: 290.9978
- Similarity Product: 182.3862164802194

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test